YD Life Sci­ence signs tech trans­fer agree­ment with KRIBB

BioSpectrum (Asia) - - ACADEMICS NEWS -

YD Life Sci­ence has signed a tech­nol­ogy trans­fer agree­ment with Korea Re­search In­sti­tute of Bio­science & Biotech­nol­ogy (KRIBB) to gain the lat­ter’s an­ti­cancer gene ther­apy using CYB5R3, a new cancer in­hibitor. Ac­cord­ing to the agree­ment, YD Life sci­ence will pay 2.5 bil­lion won ($2.1 mil­lion) to KRIBB for the sub­stance. The KRIBB team, led by Pro­fes­sor Won Mi-sun, has de­vel­oped the novel cancer in­hibitor CYB5R3 gene as a can­di­date gene ther­apy agent. The team has pro­duced ex­cel­lent an­ti­tu­mor ef­fects by con­trol­ling cancer me­tab­o­lism, and cancer mi­croen­vi­ron­ment in an an­i­mal ex­per­i­ment fo­cused on lung and col­orec­tal cancer. The team ex­pects that the can­di­date will ex­pand its in­di­ca­tion to var­i­ous cancer, in­clud­ing gas­tric, liver, prostate, pan­cre­atic cancer and brain tu­mors. The re­searchers have al­ready reg­is­tered re­lated patents in Korea and three Euro­pean coun­tries U.K., France and Ger­many and are await­ing ap­proval in the U.S. and China.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.